{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T11:01:05Z","timestamp":1743159665046},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1007\/s00115-005-1900-2","type":"journal-article","created":{"date-parts":[[2005,4,5]],"date-time":"2005-04-05T16:38:43Z","timestamp":1112719123000},"page":"999-1005","source":"Crossref","is-referenced-by-count":2,"title":["Blockade von Adh\u00e4sionsmolek\u00fclen mit Natalizumab in der Therapie der Multiplen Sklerose","Blocking adhesion molecules with natalizumab in multiple sclerosis"],"prefix":"10.1007","volume":"76","author":[{"given":"B.","family":"Schreiner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. C.","family":"Kieseier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.-P.","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Hohlfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Wiendl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1900_CR1","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1084\/jem.173.6.1553","volume":"173","author":"Bochner","year":"1991","unstructured":"Bochner BS, Luscinskas FW, Gimbrone MA Jr et al. (1991) Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. J Exp Med 173(6):1553\u20131557","journal-title":"J Exp Med"},{"key":"1900_CR2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00415-004-0332-4","volume":"251","author":"Dalton","year":"2004","unstructured":"Dalton CM, Miszkiel KA, Barker GJ et al. (2004) Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol 251(4):407\u2013413","journal-title":"J Neurol"},{"key":"1900_CR3","first-page":"1354","volume":"4","author":"Elices","year":"2003","unstructured":"Elices MJ (2003) Natalizumab. Elan\/Biogen. Curr Opin Investig Drugs 4(11):1354\u20131362","journal-title":"Curr Opin Investig Drugs"},{"key":"1900_CR4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa020732","volume":"348","author":"Ghosh","year":"2003","unstructured":"Ghosh S, Goldin E, Gordon FH et al. (2003) Natalizumab Pan-European Study Group. Natalizumab for active Crohn\u2019s disease. N Engl J Med 348(1):24\u201332","journal-title":"N Engl J Med"},{"key":"1900_CR5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1600-065X.1990.tb00561.x","volume":"114","author":"Hemler","year":"1990","unstructured":"Hemler ME, Elices MJ, Parker C et al. (1990) Structure of the integrin VLA-4 and its cell-cell and cell-matrix adhesion functions. Immunol Rev 114:45\u201365","journal-title":"Immunol Rev"},{"key":"1900_CR6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","volume":"110","author":"Hynes","year":"2002","unstructured":"Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110(6):673\u2013687","journal-title":"Cell"},{"key":"1900_CR7","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","volume":"39","author":"Jacobs","year":"1996","unstructured":"Jacobs LD, Cookfair DL, Rudick RA et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39(3):285\u2013294","journal-title":"Ann Neurol"},{"key":"1900_CR8","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/ana.410400209","volume":"40","author":"Jacobs","year":"1996","unstructured":"Jacobs LD, Cookfair DL, Rudick RA et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 40(3):480","journal-title":"Ann Neurol"},{"key":"1900_CR9","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s00115-002-1314-3","volume":"73","author":"K","year":"2002","unstructured":"K\u00fcmpfel T, Heydari N, Hohlfeld R (2002) Antegren (Natalizumab). A promising new approach to therapy of multiple sclerosis. Nervenarzt 73(6):552\u2013555","journal-title":"Nervenarzt"},{"key":"1900_CR10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0165-5728(99)00084-3","volume":"98","author":"Lee","year":"1999","unstructured":"Lee SJ, Benveniste EN (1999) Adhesion molecule expression and regulation on cells of the central nervous system. J Neuroimmunol 98(2):77\u201388","journal-title":"J Neuroimmunol"},{"key":"1900_CR11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3233\/HAB-1997-8102","volume":"8","author":"Leger","year":"1997","unstructured":"Leger OJ, Yednock TA, Tanner L et al. (1997) Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies 8(1):3\u201316","journal-title":"Hum Antibodies"},{"key":"1900_CR12","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1172\/JCI117519","volume":"94","author":"Lobb","year":"1994","unstructured":"Lobb RR, Hemler ME (1994) The pathophysiologic role of alpha 4 integrins in vivo. J Clin Invest 94(5):1722\u20131728","journal-title":"J Clin Invest"},{"key":"1900_CR13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ana.410390104","volume":"39","author":"Miller","year":"1996","unstructured":"Miller DH, Albert PS, Barkhof F et al. (1996) Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol 39(1):6\u201316","journal-title":"Ann Neurol"},{"key":"1900_CR14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJMoa020696","volume":"348","author":"Miller","year":"2003","unstructured":"Miller DH, Khan OA, Sheremata WA et al. (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348(1):15\u201323","journal-title":"N Engl J Med"},{"key":"1900_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/02648725.1992.10647886","volume":"10","author":"Mountain","year":"1992","unstructured":"Mountain A, Adair JR (1992) Engineering antibodies for therapy. Biotechnol Genet Eng Rev 10:1\u2013142","journal-title":"Biotechnol Genet Eng Rev"},{"key":"1900_CR16","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1212\/01.WNL.0000128136.79044.D6","volume":"62","author":"O","year":"2004","unstructured":"O\u2019Connor PW, Goodman A, Willmer-Hulme AJ et al. (2004) Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology 62(11):2038\u20132043","journal-title":"Neurology"},{"key":"1900_CR17","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","volume":"352","author":"PRISMS","year":"1998","unstructured":"PRISMS Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis. Lancet 352(9139):1498\u20131504","journal-title":"Lancet"},{"key":"1900_CR18","first-page":"678","volume":"353","author":"PRISMS","year":"1999","unstructured":"PRISMS Study Group (1999) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis. Lancet 353(9153):678","journal-title":"Lancet"},{"key":"1900_CR19","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s00115-002-1328-x","volume":"73","author":"Rieckmann","year":"2002","unstructured":"Rieckmann P, Toyka KV et al. (2002) Immunomodulatory staged therapy of multiple sclerosis. New aspects and practical applications. Nervenarzt 73(6):556\u2013563","journal-title":"Nervenarzt"},{"key":"1900_CR20","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1212\/WNL.53.3.444","volume":"53","author":"Schwid","year":"1999","unstructured":"Schwid SR, Noseworthy JH (1999) Targeting immunotherapy in multiple sclerosis: a near hit and a clear miss. Neurology 53(3):444\u2013445","journal-title":"Neurology"},{"key":"1900_CR21","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","volume":"43","author":"The","year":"1993","unstructured":"The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43(4):655\u2013661","journal-title":"Neurology"},{"key":"1900_CR22","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1172\/JCI11717","volume":"107","author":"Theien","year":"2001","unstructured":"Theien BE, Vanderlugt CL, Eagar TN et al. (2001) Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J Clin Invest 107(8):995\u20131006","journal-title":"J Clin Invest"},{"key":"1900_CR23","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1182\/blood-2003-03-0974","volume":"102","author":"Theien","year":"2003","unstructured":"Theien BE, Vanderlugt CL, Nickerson-Nutter C et al. (2003) Differential effects of treatment with a small-molecule VLA-4 antagonist before and after onset of relapsing EAE. Blood 102(13):4464\u20134471","journal-title":"Blood"},{"key":"1900_CR24","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1212\/WNL.53.3.466","volume":"53","author":"Tubridy","year":"1999","unstructured":"Tubridy N, Behan PO, Capildeo R et al. (1999) The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 53(3):466\u2013472","journal-title":"Neurology"},{"key":"1900_CR25","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.4049\/jimmunol.157.5.1965","volume":"157","author":"Udagawa","year":"1996","unstructured":"Udagawa T, Woodside DG, McIntyre BW (1996) Alpha 4 beta 1 (CD49d\/CD29) integrin costimulation of human T cells enhances transcription factor and cytokine induction in the absence of altered sensitivity to anti-CD3 stimulation. J Immunol 157(5):1965\u20131972","journal-title":"J Immunol"},{"key":"1900_CR26","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1172\/JCI12440","volume":"108","author":"Vajkoczy","year":"2001","unstructured":"Vajkoczy P, Laschinger M, Engelhardt B (2001) Alpha4-integrin-VCAM-1 binding mediates G protein-independent capture of encephalitogenic T cell blasts to CNS white matter microvessels. J Clin Invest 108(4):557\u2013565","journal-title":"J Clin Invest"},{"key":"1900_CR27","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1191\/1352458504ms1084oa","volume":"10","author":"Vollmer","year":"2004","unstructured":"Vollmer TL, Phillips JT, Goodman AD et al. (2004) An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis. Mult Scler 10(5):511\u2013520","journal-title":"Mult Scler"},{"key":"1900_CR28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/356063a0","volume":"356","author":"Yednock","year":"1992","unstructured":"Yednock TA, Cannon C, Fritz LC et al. (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356(6364):63\u201366","journal-title":"Nature"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-005-1900-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-005-1900-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-005-1900-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T21:03:28Z","timestamp":1683061408000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-005-1900-2"}},"subtitle":["Aktueller Studienstand"],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["1900"],"URL":"https:\/\/doi.org\/10.1007\/s00115-005-1900-2","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}